Market Overview

UPDATE: Jefferies & Company Reiterates Underperform Rating, Raises PT on Eli Lilly & Co.

Related LLY
Lipocine Inc Halted: Feds Eye Safety, Efficacy Of Testosterone
Lilly Announces CYRAMZA Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint Of Overall Survival
Eli Lilly Bets Big on Diabetes, Cancer Drugs (Fox Business)

In a report published Wednesday, Jefferies & Company reiterated its Underperform rating on Eli Lilly & Co. (NYSE: LLY), and raised its price target from $36.00 to $43.00.

Jefferies & Company noted, “We see Pharmaceuticals as remaining attractive in 2013, but unlikely to return the same level of relative performance as in 2012. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche, Pfizer and Bristol-Myers remain high conviction Buy ratings. We continue to point to Eli Lilly and GlaxoSmithKline as our least preferred names.”

Eli Lilly & Co. closed on Tuesday at $52.80.

Latest Ratings for LLY

DateFirmActionFromTo
Aug 2014Deutsche BankInitiates Coverage onBuy
Aug 2014JefferiesMaintainsHold
Aug 2014Tigress FinancialInitiates Coverage onBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (LLY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters